The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Cachexia
- Focus Therapeutic Use
- 26 Feb 2019 Status changed from active, no longer recruiting to discontinued.
- 05 Jun 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2020.
- 05 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2020.